Clinical Trial Update: Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating KPI-121 versus placebo in dry eye disease completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease
• Keratoconjunctivitis Sicca

Drugs mentioned

• KPI-121

Snippet

Sponsor: Kala Pharmaceuticals, Inc. | Conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca | Phase 3 | Status: COMPLETED | Results posted: 2020-12-03